10 completed. 10 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Completed 10 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy peginterferon beta-1a, interferon beta-1a, interferon beta-1b - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Biogen | 80 | 2017-01-30 | 2020-11-25 |
| Fingolimod Effect on Cytokine and Chemokine Levels Fingolimod 0.5 mg - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 126 | 2015-03-31 | 2019-09-30 |
| Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 alemtuzumab GZ402673 - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Genzyme, a Sanofi Company | 1062 | 2015-01-07 | 2022-03-28 |
| Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Fingolimod, Disease Modifying therapy - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 881 | 2012-06-08 | 2021-01-05 |
| Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Fingolimod, Interferon beta - 1a (IFN), Glatiramer acetate (GA) - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 298 | 2012-01-01 | 2014-08-08 |
| Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy Fingolimod (FTY720) - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 347 | 2011-12-24 | 2019-01-25 |
| Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Fingolimod, Standard MS DMT - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 61 | 2011-05-01 | 2015-06-22 |
| Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Vitamin A, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Tehran University of Medical Sciences | 36 | 2009-10-01 | 2014-03-14 |
| Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis Rebif® (clone 484-39) - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Merck KGaA, Darmstadt, Germany | 460 | 2004-05-01 | 2014-02-27 |
| Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? Interferon beta-1a - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Biogen | 284 | 1999-11-01 | 2007-12-13 |
Multiple Sclerosis, Relapsing-Remitting (10) · Multiple Sclerosis (4)
Autoimmune Diseases (10) · Autoimmune Diseases of the Nervous System (10) · Demyelinating Autoimmune Diseases, CNS (10) · Demyelinating Diseases (10) · Immune System Diseases (10) · Nervous System Diseases (10) · Multiple Sclerosis (6)
Fingolimod Hydrochloride (5) · Interferon beta-1a (5) · Glatiramer Acetate (2) · Interferon beta-1b (2) · Vitamin A (1) · peginterferon beta-1a (1) · retinol palmitate (1)
Novartis Pharmaceuticals (5) · Biogen (2) · Genzyme, a Sanofi Company (1) · Merck KGaA, Darmstadt, Germany (1) · Tehran University of Medical Sciences (1)
Australia (2) · Belgium (2) · Italy (2) · Russia (2) · Spain (2) · United Kingdom (2) · United States (2) · Argentina (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Iran (1) · Israel (1)
Ali Akbar Saboor Yaraghi, PhD (1) · Bettina Stubinski, M.D. (1) · Renato Turrini, MD (1) · Sima Jafarirad, PhD student (1)
PMID 23868508, PMID 31654272, PMID 31762387, PMID 32583052, PMID 32710396, PMID 33476880, PMID 34378446, PMID 34882037, PMID 37745914, PMID 39935588
2016 (1)